Corrigendum to "Quantitative evaluation of dichloroacetic acid kinetics in human-A physiologically based pharmacokinetic modeling investigation" [Toxicology 245 (2008) 35-48] (DOI:10.1016/j.tox.2007.12.010);Quantitative evaluation of dichloroacetic acid kinetics in human-a physiologically based pharmacokinetic modeling investigation

Toxicology

Volumn 245, Issue 1-2, 2008, Pages 35-48

  Li, Ting ^a   Schultz, Irv ^b   Keys, Deborah A ^c   Campbell, Jerry L ^a   Fisher, Jeffrey W ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b Battelle Pacific NW Division ^*  (United States)

^c Statistics and Modeling Supporting Informed Decisions   (United States)

Author keywords

DCA; Dichloroacetate; GSTzeta; Human; PBPK

Indexed keywords

DICHLOROACETIC ACID; GLUTATHIONE TRANSFERASE;

ARTICLE; CALIBRATION; CANCER RISK; CHEMICAL MODEL; CHEMICAL REACTION KINETICS; CONTROLLED STUDY; COVALENT BOND; DRUG CLEARANCE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG TRANSFORMATION; DRUG UPTAKE; ENZYME DEGRADATION; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME SYNTHESIS; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LIVER; MALE; MICHAELIS CONSTANT; MOUSE; NONHUMAN; NONLINEAR SYSTEM; NORMAL HUMAN; PHARMACOKINETICS; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; QUANTITATIVE ANALYSIS;

ANIMALIA; MUS; RATTUS; RODENTIA;

EID: 39549117779     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2008.03.001     Document Type: Erratum

References (42)

1. Abbas R., and Fisher J.W. A physiologically based pharmacokinetic model for trichloroethylene and its metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol, and trichloroethanol glucuronide in B6C3F1 mice. Toxicol. Appl. Pharmacol. 147 (1997) 15-30
2. Ammini C.V., Fernandez-Canon J., Shroads A.L., Cornett R., Cheung J., James M.O., Henderson G.N., Grompe M., and Stacpoole P.W. Pharmacologic or genetic ablation of maleylacetoacetate isomerase increases levels of toxic tyrosine catabolites in rodents. Biochem. Pharmacol. 66 (2003) 2029-2038
3. Anderson W.B., Board P.G., and Anders M.W. Glutathione transferase zeta-catalyzed bioactivation of dichloroacetic acid: reaction of glyoxylate with amino acid nucleophiles. Chem. Res. Toxicol. 17 (2004) 650-662
4. Anderson W.B., Board P.G., Gargano B., and Anders M.W. Inactivation of glutathione transferase zeta by dichloroacetic acid and other fluorine-lacking alpha-haloalkanoic acids. Chem. Res. Toxicol. 12 (1999) 1144-1149
5. Anderson W.B., Liebler D.C., Board P.G., and Anders M.W. Mass spectral characterization of dichloroacetic acid-modified human glutathione transferase zeta. Chem. Res. Toxicol. 15 (2002) 1387-1397
6. Barton H.A., Bull R., Schultz I., and Andersen M.E. Dichloroacetate (DCA) dosimetry: interpreting DCA-induced liver cancer dose response and the potential for DCA to contribute to trichloroethylene-induced liver cancer. Toxicol. Lett. 106 (1999) 9-21
7. Blackburn A.C., Coggan M., Tzeng H.F., Lantum H., Polekhina G., Parker M.W., Anders M.W., and Board P.G. GSTZ1d: a new allele of glutathione transferase zeta and maleylacetoacetate isomerase. Pharmacogen 11 (2001) 671-678
8. Boorman G.A., Dellarco V., Dunnick J.K., Chapin R.E., Hunter S., Hauchman F., Gardner H., Cox M., and Sills R.C. Drinking water disinfection byproducts: review and approach to toxicity evaluation. Environ. Health Perspect. 107 (1999) 207-217
9. Brown R.P., Delp M.D., Lindstedt S.L., Rhomberg L.R., and Beliles R.P. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Indust. Health 13 (1997) 407-484
10. Campbell J.L., and Fisher J.W. A PBPK Modeling assessment of the competitive metabolic interactions of JP-8 vapor with two constituents, m-xylene and ethylbenzene. Inhal. Toxicol. 19 (2007) 265-273
11. Chu, P.I., 1987. Pharmacokinetics of sodium dichloroacetics. Ph. D. Dissertation. College of Pharmacy. University of Florida, Gainesville, FL.
12. Clewell H.J., Gentry P.R., Covington T.R., and Gearhart J.M. Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. Environ. Health Perspect. 108 (2000) 283-305
13. Clewell R.A., Merrill E.A., Yi K.Y., Mahle D.A., Sterner T.R., Fisher J.W., and Gearhart J.M. Predicting neonatal perchlorate dose and inhibition of iodide uptake in the rat during lactation using physiologically-based pharmacokinetic modeling. Toxicol. Sci. 74 (2003) 416-436
14. Cornett R., James M.O., Henderson G.N., Cheung J., Shroads A.L., and Stacpoole P.W. Inhibition of glutathione S-transferase zeta and tyrosine metabolism by dichloroacetate: a potential unifying mechanism for its altered biotransformation and toxicity. Biochem. Biophys. Res. Commun. 262 (1999) 752-756
15. Curry S.H., Lorenz A., Chu P.I., Limacher M., and Stacpoole P.W. Disposition and pharmacodynamics of dichloroacetate (Dca) and oxalate following oral Dca doses. Biopharm. Drug Dispos. 12 (1991) 375-390
16. DeAngelo A.B., George M.H., and House D.E. Hepatocarcinogenicity in the male B6C3F1 mouse following a lifetime exposure to dichloroacetic acid in the drinking water: dose-response determination and modes of action. J. Toxicol. Environ. Health A 58 (1999) 485-507
17. Fisher J.W., Mahle D.A., and Abbas R. A human physiological based pharmacokinetic model for trichloroethylene and its matabolites, trichloroacetic acid and free trichloroethanol. Toxicol. Appl. Pharmacol. 152 (1998) 339-359
18. Fox A.W., Sullivan B.W., Buffini J.D., Neichin M.L., Nicora R., Hoehler F.K., Orourke R., and Stoltz R.R. Reduction of serum lactate by sodium dichloroacetate, and human pharmacokinetic-pharmacodynamic relationships. J. Pharmacol. Exper. Therap. 279 (1996) 686-693
19. Greenberg M.S., Burton G.A., and Fisher J.W. Physiologically based pharmacokinetic modeling of inhaled trichloroethylene and its oxidative metabolites in B6C3F(1) mice. Toxicol. Appl. Pharmacol. 154 (1999) 264-278
20. Gustafson D.L., Rastatter J.C., Colombo T., and Long M.E. Doxorubicin pharmacokinetics: macromolecule binding, metabolism, and excretion in the context of a physiologic model. J. Pharm. Sci. 91 (2002) 1488-1501
21. Jia M.H., Coats B., Chadha M., Frentzen B., Perez-Rodriguez J., Chadik P.A., Yost R.A., Henderson G.N., and Stacpoole P.W. Human kinetics of orally and intravenously administered low-dose 1,2-C-13-dichloro acetate. J. Clin. Pharmacol. 46 (2006) 1449-1459
22. Keys D.A., Schultz I.R., Mahle D.A., and Fisher J.W. A quantitative description of suicide inhibition of dichloroacetic acid in rats and mice. Toxicol. Sci. 82 (2004) 381-393
23. Lantum H.B.M., Cornejo J., Pierce R.H., and Anders M.W. Perturbation of maleylacetoacetic acid metabolism in rats with dichloroacetic acid-induced glutathione transferase zeta deficiency. Toxicol. Sci. 74 (2003) 192-202
24. Larson J.L., and Bull R.J. Metabolism and lipoperoxidative activity of trichloroacetate and dichloroacetate in rats and mice. Toxicol. Appl. Pharmacol. 115 (1992) 268-277
25. Lilly P.D., Thornton-Manning J.R., Gargas M.L., Clewell H.J., and Andersen M.E. Kinetic characterization of CYP2E1 inhibition in vivo and in vitro by the chloroethylenes. Arch. Toxicol. 72 (1998) 609-621
26. Lim C.E.L., Matthaei K.I., Blackburn A.C., Davis R.P., Dahlstrom J.E., Koina M.E., Anders M.W., and Board P.G. Mice deficient in glutathione transferase zeta/maleylacetoacetate isomerase exhibit a range of pathological changes and elevated expression of Alpha, Mu, and Pi class glutathione transferases. Am. J. Pathol. 165 (2004) 679-693
27. Lukas G., Vyas K.H., Brindle S.D., Lesher A.R., and Wagner W.E. Biological disposition of sodium dichloroacetate in animals and humans after intravenous administration. J. Pharm. Sci. 69 (1980) 419-421
28. Merrill E.A., Clewell R.A., Robinson P.J., Jarabek A.M., Gearhart J.M., Sterner T.R., and Fisher J.W. PBPK model for radioactive iodide and perchlorate kinetics and perchlorate-induced inhibition of iodide uptake in humans. Toxicol. Sci. 83 (2005) 25-43
29. Mori M., Yamagata T., Goto T., Saito S., and Momoi M.Y. Dichloroacetate treatment for mitochondrial cytopathy: long-term effects in MELAS. Brain Dev. 26 (2004) 453-458
30. Schultz I.R., Merdink J.L., Gonzalez-Leon A., and Bull R.J. Comparative toxicokinetics of chlorinated and brominated haloacetates in F344 rats. Toxicol. Appl. Pharmacol. 158 (1999) 103-114
31. Schultz I.R., Merdink J.L., Gonzalez-Leon A., and Bull R.J. Dichloroacetate toxicokinetics and disruption of tyrosine catabolism in B6C3F1 mice: dose-response relationships and age as a modifying factor. Toxicology. 173 (2002) 229-247
32. Schultz I.R., and Shangraw R.E. Effect of short-term drinking water exposure to dichloroacetate on its pharmacokinetics and oral bioavailability in human volunteers: a stable isotope study. Toxicol. Sci. 92 (2006) 42-50
33. Shangraw R.E., and Fisher D.M. Pharmacokinetics and pharmacodynamics of dichloroacetate in patients with cirrhosis. Clin. Pharmacol. Ther. 66 (1999) 380-390
34. Stacpoole P.W., Henderson G.N., Yan Z.M., Cornett R., and James M.O. Pharmacokinetics, metabolism, and toxicology of dichloroacetate. Drug Metab. Rev. 30 (1998) 499-539
35. Stacpoole P.W., Henderson G.N., Yan Z.M., and James M.O. Clinical pharmacology and toxicology of dichloroacetate. Environ. Health Perspect. 106 (1998) 989-994
36. Tong Z., Board P.G., and Anders M.W. Glutathione transferase zeta-catalyzed biotransformation of dichloroacetic acid and other alpha-haloacids. Chem. Res. Toxicol. 11 (1998) 1332-1338
37. Tong Z., Board P.G., and Anders M.W. Glutathione transferase Zeta catalyses the oxygenation of the carcinogen dichloroacetic acid to glyoxylic acid. Biochem. J. 331 (1998) 371-374
38. Tzeng H.F., Blackburn A.C., Board P.G., and Anders M.W. Polymorphism- and species-dependent inactivation of glutathione transferase zeta by dichloroacetate. Chem. Res. Toxicol. 13 (2000) 231-236
39. Uden P.C., and Miller J.W. Chlorinate acids and chloral in drinking-water. J. Am. Water Works Assoc. 75 (1983) 524-527
40. U.S. Environmental Protection Agency (U.S. EPA), 2002. National Primary Drinking Water Regulations. Fed Registr Sec.141.64, 430.
41. U.S. Environmental Protection Agency (U.S. EPA), 2003. Toxicological Review of Dichloroacetic Acid. U.S. Envirometnal Protection Agency, Washington, DC. EPA 635/R-03/007.
42. Wells P.G., Moore G.W., Rabin D., Wilkinson G.R., Oates J.A., and Stacpoole P.W. Metabolic effects and pharmacokinetics of intravenously administered dichloroacetate in humans. Diabetol. 19 (1980) 109-113